Bangkok, 12 July Despite the clear benefits for patients and the high rates of resistance in the west, new research has shown that currently only 1 out of 5 eligible patients is benefiting from the latest HIV breakthrough, FUZEON, primarily due to the need to inject the drug. At the International AIDS Conference in Bangkok today, new guidance will be presented on how healthcare professionals and patients can work together to effectively incorporate FUZEON into patients' daily treatment routine.

"FUZEON is a revolutionary therapy and for the majority of patients the significant improvements in health far outweigh the burden of the injection. It is alarming that many of these patients offered FUZEON are not accepting the offer due to the fear of injection and are missing out on the modern era of HIV therapy," comments Professor Joep Lange, President of the International AIDS Society.

Comprehensive FUZEON benefits seen by 3 months and maintained at 2 years

Dramatic FUZEON virological benefits can be seen as early as 1 week. Within just 3 months, FUZEON patients are twice as likely to achieve undetectable levels of HIV compared to those who are not taking FUZEON. Furthermore, data show these benefits are maintained at 2 years. FUZEON patients also reported approximately half the incidence of diarrhoea, a common and often debilitating side effect associated with HIV therapy.

"We urge physicians and nurses to work closely with their patients during the first 3 months of FUZEON therapy, by which time dramatic benefits should be seen and self injection should have become routine," comments Dr Mike Youle, Royal Free Hospital, London.

The pivotal role of physicians and nurses

"It is essential that, as physicians, we present FUZEON to all triple class experienced patients, balancing the remarkable improvements in viral load, CD4 count and quality of life, with the need for self-injection. Our challenge is to iden
'"/>


11-Jul-2004

Page: 1 2 3
Related medicine news :

1. Study of hip replacement patients finds 80 percent eligible for minimally invasive surgery
2. UCLA researchers release profile of proposition 36-eligible drug offenders
3. Patients who need cardiac resynchronization therapy may be eligible for Cedars-Sinai clinical trials
4. Parents language barrier may prevent eligible children from receiving government-sponsored health insurance, says study
5. Hormonal treatment improves survival in high-risk prostate cancer patients
6. Study finds that coordinating care of chronically ill patients does not increase liability
7. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
8. Optical technique identifies vulnerable plaques in cardiac patients
9. NHS target driven culture is failing patients
10. Cardiac deaths peak in sleep hours for patients with sleep apnea
11. Chronic fatigue patients show lower response to placebos